Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gentamicin + penicillin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination antibiotic therapy that demonstrates synergistic activity against various bacterial infections. Penicillin, a beta-lactam antibiotic, inhibits bacterial cell wall synthesis, increasing cell wall permeability. This enhanced permeability facilitates the entry of gentamicin, an aminoglycoside that inhibits bacterial protein synthesis. This combined action leads to enhanced bactericidal activity and is particularly valuable in treating serious infections such as enterococcal endocarditis, meningitis, neonatal sepsis, and severe respiratory infections. It also shows effectiveness against Group B streptococcal and Pseudomonas infections.
- Other names
- gentamycin + penicillin
02
Targets
Beyond the preview
Go deeper on gentamicin + penicillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gentamicin + penicillin.